568513-U

Discovery^® HS C18 (5 µm) HPLC Columns

L × I.D. 25 cm × 4 mm, HPLC Column

• Synonym(s): Discovery RP18 HPLC Column
• UNSPSC Code: 41115700
• eCl@ss: 32110501
• NACRES: SB.52

Properties

• product name: Discovery^® HS C18 HPLC Column, 5 μm particle size, L × I.D. 25 cm × 4 mm
• material: stainless steel column
• Agency: suitable for USP L1
• product line: Discovery^®
• feature: endcapped
• manufacturer/tradename: Discovery^®
• packaging: 1 ea of
• extent of labeling: 20% Carbon loading
• parameter: ≤70 °C temp. range; 400 bar pressure (5801 psi)
• technique(s): HPLC: suitable; LC/MS: suitable
• L × I.D.: 25 cm × 4 mm
• surface area: 300 m²/g
• surface coverage: 3.2 μmol/m²
• impurities: <10 ppm metals
• matrix: silica gel, high purity, spherical particle platform; fully porous particle
• matrix active group: C18 (octadecyl) phase
• particle size: 5 μm
• pore size: 120 Å
• operating pH range: 2-8
• application(s): food and beverages
• separation technique: reversed phase

Description

Application

• A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies.: This research developed a robust RP-HPLC method for the quantitative analysis of molnupiravir, a COVID-19 therapeutic, utilizing nanoformulations. The study highlights the method′s stability and effectiveness in permeability studies, demonstrating its potential in pharmaceutical analysis (Reçber et al., 2022).


• Analysis of terizidone in plasma using HPLC-UV method and its application in a pharmacokinetic study of patients with drug-resistant tuberculosis.: The study developed and validated an HPLC-UV method for analyzing terizidone in plasma, essential for pharmacokinetic studies in patients with drug-resistant tuberculosis. The method′s reliability supports its use in clinical and pharmacological research (Mulubwa and Mugabo, 2018).


• Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies.: This research focuses on optimizing a liquid chromatography method to quantify doxorubicin in plasma and urine. It is crucial for pharmacokinetic, biomedical, and drug monitoring studies, ensuring accurate and precise therapeutic monitoring (Maliszewska et al., 2018).


• Universal efavirenz determination in transport study, rat placenta perfusion and placenta lysate by HPLC-UV.: This study introduces a universal HPLC-UV method for determining efavirenz in various biological matrices, including transport studies, rat placenta perfusion, and lysate. It is significant for pharmacokinetic and drug distribution research (Zelena et al., 2017).

Features and Benefits

• Stable, low bleed for LC-MS applications
• Scalable from analytical to preparatory
• Highly stable to ensure excellent run-to-run and lot-to-lot reproducibility
• Higher hydrophobicity for better resolution of difficult analytes

   

Recommended products

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany